Clinical Trials

RTX-240 for the Treatment of Advanced Solid Tumors

Study Title
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors
Status

Enrolling

Primary Objectives
  1. Safety Assessment
  2. Pharmacodynamics of RTX-240 will be evaluated through changes in natural killer and T cell numbers relative to baseline
  3. Anti-Tumor activity of RTX-240 measured by Overall Response Rate, or ORR

If you are a patient or a loved one interested in learning more about RTX-240 for the treatment of cancer or participating in a clinical trial, please visit www.rubiustrials.com.